Johnson & Johnson reported a higher-than-expected third-quarter 2017 profit and raised its full-year forecast as the company gained from strong sales of its new cancer drugs.
Pfizer Inc. announced that the company is reviewing strategic alternatives for its Consumer Healthcare business.
GlaxoSmithKline provided information about its second-quarter financials this week. The attention focused on plans to kill more than 30 preclinical and clinical programs and allocate 80 percent of its research-and-development budget to respiratory and HIV/infectious diseases. But a closer look at new CEO Emma Walmsley’s plans point to big changes in the company’s manufacturing network as well.
GSK’s new chief executive announced plans to narrow the focus of the group’s drug research by ditching 30-plus projects to improve returns in its core pharma business.
Johnson & Johnson is seizing upon a U.S. Supreme Court ruling limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer.
Johnson & Johnson reported disappointing pharmaceutical and consumer product sales for first-quarter 2017 as revenue missed analyst estimates.
Takeda Pharmaceutical has entered into an agreement to transfer its Japan Consumer Healthcare Business Unit to Takeda Consumer Healthcare.
Drugmaker Ipsen has agreed to buy five consumer healthcare products from bigger French rival Sanofi for 83 million euros ($88 million), in a deal which Ipsen said should boost its profits.
GlaxoSmithKline said it had chosen its head of consumer healthcare, Emma Walmsley, as its new chief executive after several months of reviewing candidates.
Paris-based Sanofi and Germany-based Boehringer Ingelheim have agreed to exchange Sanofi’s Merial animal drugs business with Boehringer’s over-the-counter drugs business.
